Partner Sites


Logo BusinessBecause - The business school voice
mobile search icon

From Startup To $67 Billion Company | 3 Lessons From Moderna's Vaccine Success

Pre-pandemic, biotech company Moderna had never launched a product. Now the company’s vaccine has propelled its market capitalization to $67 billion. Here are three lessons from Moderna’s success

Wed Apr 21 2021

BusinessBecause
Moderna is one of the success stories of the coronavirus pandemic. The US government has bought 300 million doses of its vaccine, which provides up to 94% protection from the virus and has been central to the US providing a first vaccination dose to half of its population.

But in March 2020, Moderna was little more than a biotech startup. It had never taken a product to market, and the company didn’t even have a credit rating.

In April 2020, the US government decided to invest in Moderna’s unproven, but potentially innovative, mRNA vaccine technology. This risky public-private partnership began with $483 million of government investment, which has now risen to $4.5 billion. Moderna’s subsequent success has seen its market capitalization rise as high as $67 billion, at the time of writing. 

What can Moderna’s success teach us about public-private partnerships? Leading business school professors from Duke’s Fuqua School of Business, NYU Stern School of Business, ESMT Berlin, and Johns Hopkins Carey Business School reveal what they think. 


1. Moonshot investments are worth it 

0ca6b4e7544c833e5e2dcb51cefe64aeca55a7c5.png

Moderna’s innovative mRNA technology allows vaccines to be created without putting weakened or dormant germs into our bodies—the traditional method. Instead, the vaccine teaches our cells to create proteins that trigger an immune response that creates the antibodies needed to fight infection. 

Both the Moderna and Pfizer/BioNTech vaccines use this technology. Pfizer’s mRNA technology was developed by BioNTech, another small biotech firm. While traditional vaccines like those created by Oxford/Astrazeneca and Johnson & Johnson had trial results showing around 70% efficacy, both mRNA vaccines were more than 90% efficient. 

The success of mRNA-based vaccines is down to startups often being more innovative than established companies, thinks David Ridley (pictured above, right), professor of business and healthcare management at Duke University's Fuqua School of Business.

“So much innovation comes from smaller players,” he says, “there are so many ideas out there and we shouldn’t expect big players to have a monopoly on them.” 

This reinforces a growing trend towards governments making more risky investments in ambitious, disruptive innovations coined ‘moonshots’. With moonshot investments, the potential for success and near-term profitability is low, but the potential rewards are extremely high.

d8f4c929d45491f84e304c4aaba9fb4c081eda8a.png

The US government is ramping up its moonshot investments through initiatives like the Defense Advanced Response Projects Agency (DARPA), which searches for new disruptive technologies. Similarly, the UK government has floated plans for its own high risk investment agency. Both are looking for the next wave of disruptive tech.

Ari Ginsberg, professor of entrepreneurship and management at NYU Stern School of Business, supports governments being prepared to make more risky, moonshot investments.

“There is a risk/reward tradeoff in investment decisions and the higher the potential return, the more justifiable is the higher level of risk,” he says.


2. Governments should balance investment with incentives

Risky public-private partnerships can backfire. In 2006 the German and French governments invested in Quaero, a search engine project billed as an alternative to Google. Though after a string of issues, it was abandoned in 2013 along with $298 million of investment. 

Such examples show that governments aren’t always best placed to identify disruptive technologies, says Stefan Wagner, associate professor of strategy and innovation at ESMT Berlin. 

“I am skeptical that the state is the best actor to choose promising technologies,” he says.

While governments have responsibilities beyond investing in disruptive and innovative technologies, professional investors like venture capitalists and institutional investors have the training and expertise to be better placed to make these decisions, Stefan (pictured below, right) thinks. 

A less risky tactic would be to offer companies incentives to engage in research and development (R&D) projects, and rewards for reaching certain targets. Offering ‘pull incentives’, rather than ‘push funding’. 

dc80c517e95c459cdca6656611769c0cb356d027.png

“The state could say if you engage in R&D activity you get an advantage when it comes to the question of how much taxes you have to pay,” he says.

In the case of Moderna, the US government offered a combination of these approaches, providing initial investment for the company to help bring its vaccine candidate to trial, as well as pledging to buy 100 million doses of the vaccine once it was produced. 

This combination of both push and pull mechanisms is the best approach for public-private partnerships, believes David from Duke Fuqua. 

“I think it is absolutely the right approach for governments to fund some early-stage research and also offer prizes for successful development, both the push and the pull,” he says.   

“The combination [with Moderna] yielded enormous returns for public health and the economy.” 


960e77502f72f6267fce4901cbc790d70a6717d2.png


3. Governments should support low profit research areas 

Potentially innovative and important advances in healthcare are often ignored by investors and venture capitalists because of slow return on investment and high risk of failure. 

It can take decades for a technology to be brought into use. Research into mRNA technology began in the early 1990s, and even before the pandemic it was unclear whether the technology would be successful. For investors, who have to provide quick returns to their shareholders, this isn’t always worth the wait. 

In areas with potential public health benefits that are unattractive to investors, governments have a responsibility to provide support, says Bonnie Robeson, senior lecturer at Johns Hopkins Carey Business School. 

1ba1496d62659e31cfb687c7e6a1d9f1cd7016d6.png

“Pharmaceutical development and therapeutics is a very challenging, high risk area, so this is a way to share that risk,” she says.  

Despite the risks of a project failing altogether, the investment is still worth it, she thinks. “There is always a risk of failure, but I don’t see any issues because the government is always looking out for the population’s health and wellbeing.” 

In the case of Moderna, supporting the innovative technology has had a huge impact in the fight against the pandemic, but the potential doesn’t stop there. 

mRNA can be used as a platform to fight all kinds of disease. Moderna currently has plans for 24 new mRNA vaccine candidates—13 of which are undergoing trials—for diseases ranging from heart disease to cancer. The rewards from this public-private partnership are potentially only just beginning. 


Read next:

Will COVID-19 Vaccine Success Inspire Future Coopetition?


BB Insights explores the latest research and trends from the business school classroom, drawing on the expertise of world-leading professors to inspire and inform current and future leaders

Student Reviews

Duke University Fuqua School of Business

Student

Verified

31/10/2023

On Campus

Supportive atmosphere

The professors at Duke university exhibit exceptional commitment to the success and well-being of their students by ensuring their academic growth and fostering a supportive social atmosphere. Moreover, the entire community is recognized for its amicability and inclusiveness.

Maxwell

Verified

30/03/2023

On Campus

Diversity

The people or the students are without a doubt Duke's greatest asset. While all students are driven to succeed, they are also enthusiastic about a variety of hobbies. You run across a huge lot of diversity. It is the ideal example of a school with well-rounded students and the ideal balance of campus life in a metropolis.

Anabelle

Verified

27/02/2023

On Campus

Happy to school

All I could ever hope for is Duke University. That really epitomizes the "work hard, play hard" philosophy that elite colleges frequently pursue. Even though you'll have a lot of schooling to complete over the week, it's simple to keep focused because all of your friends are putting in similar amounts of effort. Many events taking place on and around campus on the weekends provide a great way to unwind. The combination of demanding academics and traditional college fun strikes the perfect balance.

Monica

Verified

27/02/2023

On Campus

Good schooling

Living, eating, learning, and developing who you want to be as an adult are all fantastic at Duke. I participated in student athletics, and I couldn't have asked for a better interaction with the faculty and other students. I appreciate all of the help I get from the Duke community more than anything. Furthermore, the teachers take the time to get to know you, and the lectures are diverse and demanding (if you do the same). I'd give it a 10 out of 10.

Aline

Verified

26/11/2022

On Campus

Beautiful School, Nice Classes

DU remains one the greatest and best universities that I have ever stepped in. The school is beautiful and neat. The classes are spacious and also very nice. I enjoyed attending my Lectures in those lecture halls. I also loved the Lecturers because of the good work they did. The university also has very good dorms that are given to students on first come first serve basis and they are affordable

Student

Verified

29/06/2022

Blended

Amazing experience

I received my B.S. in Biology and B.A. in Global Health with a minor in Chemistry from Duke University. I was able to grow as a student, scientist, and global health advocate with the help of my friends, professors, and other mentors I met along the way. A lot to learn if you look and ask, a great place to learn for those who want to learn.

Student

Verified

29/06/2022

Blended

whirlwind of growth and change

An amazing 2 years, with covid and everything else happening Duke has been a place of growth for me. The courses , classes were one of a kind, online and on campus. But the valuable lessons learned in the classes are irreplicable. The students are amazing here, so much diversity , I had no problem fitting in. The teachers are down right brilliant and so helpful. Don't be afraid to ask them anything. Graduated with my MBA with Duke and now my future awaits.

Student

Verified

29/06/2022

On Campus

One of the best for Business students

Graduated with an MBA. The classes were very insightful and engaging. The staff are very easy to deal with. The teachers and students, are truly amazing people. Grateful to all the people I've met along the way at Duke. I've learnt a great deal that will help me in my future endeavors. The campus itself is a marvel, it is beautiful.

Student

Verified

16/06/2022

On Campus

The university campus is awesome

I graduated with a masters degree in Religious Studies from Duke University. One thing I really liked about the university is its huge campus. It is spread in a large area with a lot of greenery and also have the facilities of reading rooms for single person also. My department building was very well taken care of. The library is immensely populated with books for all your needs. The faculty is very nice to students. The classes are equipped with latest technology to cater the needs of students. The University also provides room rentals for international students. They are very well maintained and priority is given to the International students for a comfortable stay there. There are weekly events conducted by the University as well as Student clubs for the entertainment of students. Anybody can take part in them and show their talents. I enjoyed my degree and I graduated in 2021 and was very happy that I had graduated from a reputed University.

RECAPTHA :

a1

fe

fd

4b